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We investigated the relationship between 18F-fluorodeoxyglucose positron emission
tomography-computed tomography (18F-FDG-PET-CT) standardized uptake value (SUV)
and 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative
breast cancer.
Materials and methods
One hundred sixty-seven patients were identified among those who underwent preoperative
18F-FDG-PET-CT and had RS. Maximum SUV was obtained from 18F-FDG-PET-CT; the
cut-off point was 4.
Results
The continuous RS and SUV correlated positively (Pearson’s R = 0.555; P < 0.001). An
inverse correlation was found between progesterone receptor (PR) expression by reverse
transcriptase-polymerase chain reaction, and SUV (Pearson’s R = -0.408; P < 0.001). Good
agreement between dichotomized RS (<26 vs.26) and SUV (<4 vs.4) was observed in
137 of 167 patients (82.0%; 95% confidence interval [CI], 76.2–87.9). Among patients with
low SUV, 114 of 115 (99.1% [95% CI, 97.4–100.0]) had tumors with lower RS (<26). Although
23 of 52 women (44.2% [95% CI, 30.7–57.7]) with high SUV had higher RS (26), all 13
women with high RS (31) had high-SUV tumors. Most cases with disagreements between
SUV and RS (n = 30) were classified as high SUV/lower RS (n = 29). The discordant group
had higher grade or elevated Ki67 expression (20%) compared with the low SUV/lower RS







Citation: Ahn SG, Lee J-H, Lee HW, Jeon TJ, Ryu
YH, Kim KM, et al. (2017) Comparison of
standardized uptake value of 18F-FDG-PET-CT with
21-gene recurrence score in estrogen receptor-
positive, HER2-negative breast cancer. PLoS ONE
12(4): e0175048. https://doi.org/10.1371/journal.
pone.0175048
Editor: Chin-Tu Chen, University of Chicago,
UNITED STATES
Received: November 22, 2016
Accepted: March 20, 2017
Published: April 18, 2017
Copyright: © 2017 Ahn et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This research was supported by the Basic
Science Research Program through the National
Research Foundation of Korea (NRF), funded by
the Ministry of Education, Science and Technology
(grant 2013R1A1A2007759), the Basic Science
Research Program through the NRF, funded by the
Ministry of Science, ICT, & Future Planning (NRF-
group (n = 109), but higher PR expression compared with the high SUV/higher RS group (n =
23). Multiple logistic regression analysis showed that high SUV were associated with higher
RS (26).
Conclusions
SUV, as a biologic parameter represented using a continuous variable, was found to associ-
ate with RS in ER-positive, HER2-negative breast cancer. Further studies may reveal the
biology underlying the discordance between the markers.
Introduction
The 21-gene recurrence score (RS), which quantifies the likelihood of distant recurrence in
tamoxifen-treated patients with estrogen receptor (ER)-positive breast cancer, was initially
developed as a prognostic marker [1]. Subsequently, the RS became the first clinically validated
multi-gene assay that could identify patients with ER-positive breast cancer who might benefit
from adjuvant chemotherapy [2]. RS has been incorporated into clinical guidelines concerning
treatment decisions and has become widespread in actual practice [3,4]. This test has led to
sparing patients from chemotherapy and has increased confidence in decision making for
patients with early ER-positive cancer [5].
Among patients with hormone receptor (HR)-positive breast cancer, we previously showed
that tumors with elevated glucose uptake levels have a higher risk of recurrence [6,7]. In those
studies, the prognostic influence of the standardized uptake value (SUV) on 18F-fluorodeoxy-
glucose positron emission tomography/computed tomography (18F-FDG-PET-CT), which
represents glucose uptake, was found to be more significant than subtyping based on immuno-
histochemical (IHC) markers or tumor burden. Moreover, the associations of high SUV with
high histologic grade and high Ki67 index were highly reproducible in luminal cancers [8–10].
Therefore, we postulated that the SUV might positively correlate with the RS.
To address this hypothesis, we investigated the association between the SUV on 18F-FDG-
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history of contralateral breast cancer. Finally, 162 women remained eligible for the analysis
(Fig 1).
For our IHC study of four markers, formalin-fixed, paraffin-embedded tissue sections
obtained from surgical specimens were stained with appropriate antibodies specific for the ER
(1:100 clone 6F11; Novocastra, Newcastle upon Tyne, UK), progesterone receptor (PR; clone
16; Novocastra), HER2 (4B5 rabbit monoclonal antibody; Ventana Medical Systems, Tucson,
AZ, USA), and Ki-67 (MIB-1; Dako, Glostrup, Denmark). ER and PR IHC test results were
stratified into four groups using the modified Allred system: strong, Allred score 7–8; moder-
ate, Allred score 5–6; weak, Allred score 2–4; and negative, Allred score 0–1 [11]. The HER2
status was considered positive with a score of 3+ and negative with a score of 0 or 1+ [12].
Tumors with a score of 2+ were sent for fluorescent in situ hybridization (FISH) analysis
according to the protocol given by the supplier (PathVysion kit; Vysis, Downers Grove, IL,
USA or HER2 inform; Ventana). Ki67 expression was measured by an experienced pathologist
and presented as a percentage score (range 0–100%) of positive tumor cells.
Oncotype DX
RS is calculated by the Oncotype Dx assay. It is a continuous score that is classified into the fol-
lowing categories: low risk (RS< 18), intermediate risk (RS 18–30), and high risk (RS31).
The Oncotype DX assay was performed using RNA extracted from formalin-fixed paraffin-
embedded tissue and supplied by Genomic Health (Redwood City, CA, USA). After a review
of hematoxylin and eosin-stained slides to determine whether sufficient invasive breast cancer
was present and whether manual microdissection was indicated, RNA was extracted from the
unstained sections. Cases with no cancer (depleted by prior tissue studies) or with cancer cells
occupying <5% of the section area were excluded from the assay [1]. All tissues from patients
in this study were successfully analyzed. Quantitative single gene scores for ER and PR mRNA
expression, determined via reverse transcriptase-polymerase chain reaction, were also pro-
vided by Genomic Health within the final assay report. Normalized ER and PR expression
cycle threshold levels (CT) were provided as ER scores and PR scores.
18F-FDG-PET-CT
Prior to FDG-PET-CT, each patient was asked to fast for a minimum of 8 hours, and blood
glucose levels were controlled to<130 mg/dl. Patients received an intravenous injection of
18F-FDG (5.5 MBq/kg of body weight) in the arm contralateral to the primary tumor. After
initial low-dose CT (Discovery Ste, 30 mA, 130 kVp; Biograph TruePoint, 36 mA, 120 kVp), a
PET scan was obtained from the neck to the proximal thighs, using a Philips Allegro PET
Fig 1. Consort chart.
https://doi.org/10.1371/journal.pone.0175048.g001
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camera (Philips Medical Systems, Cleveland, Ohio, USA) with an acquisition time of 3 min
per bed position in three-dimensional mode. The delay between 18F-FDG injection and PET
imaging is consistently controlled as 60 minutes. PET images were reconstructed using
ordered subset expectation maximization with attenuation correction. For semi-quantitative
evaluations, maximum SUV were calculated by measuring the 18F-FDG absorption by tumors
in the region of interest. The cross-calibration between the PET and the dose calibrator was
conducted monthly. All 18F-FDG-PET-CT scans were reviewed by three nuclear medicine
radiologists who were blinded to the RS results.
Statistical analysis
The primary objective of this study was to test the correlation between continuous RS and con-
tinuous SUV. The SUV cut-off point of 4 was determined according to previous studies [6,7].
Pearson’s R was calculated to measure the correlative value between the scores. Discrete vari-
ables were compared using the χ2 test or Fisher’s exact test. Student’s t-test or a one-way analy-
sis of variation (ANOVA) test was used to compare means. Variables with a statistical
significance in the univariate analysis were included in the multiple logistic regression analysis
and backward elimination was taken to arrive at the final model. SPSS version 18 (SPSS Inc.,
Chicago, IL, USA) was used to perform the statistical analyses. Statistical significance was
defined as a P-value <0.05.
Results
Baseline characteristics
The baseline patient characteristics are presented in S1 Table. One hundred and sixty-seven
patients with ER-positive, HER2-negative tumors were included in the analyses. The median
age of these patients was 48 years (range: 28–72 years). Sixteen patients had node-positive dis-
ease, and five had micrometastases. No patient in the study population had a stage higher than
IIB.
Ninety-seven (56.8%), 57 (35.2%), and 13 patients (8.0%) had a low, intermediate, and high
RS, respectively. Furthermore, 52 patients (32.1%) had tumors with high-SUV (4), whereas
110 (67.9%) had tumors with low SUV (<4).
Correlation between continuous SUV and continuous RS
Pearson’s R test was performed to explore the relationship between continuous SUV and con-
tinuous RS. A significant positive correlation was observed between the two continuous
parameters (Pearson’s R = 0.555; P< 0.001; Fig 2A). In analyses of ER and PR scores, a certain
degree of inverse correlation was observed between the continuous SUV and PR score (Pear-
son’s R = -0.408; P< 0.001; Fig 2B), whereas no significant correlation was observed between
the continuous SUV and ER score (Pearson’s R = -0.014; P = 0.856; Fig 2C).
Correlation between categorized SUV and categorized RS
Of the 115 patients with low-SUV tumors, 78 (67.8%) had tumors with a low RS and 37
(32.2%) had an intermediate RS (Table 1). None of the patients had high-RS tumor. Of the 52
patients with high-SUV tumors, 19 (36.4%) had a low RS, 20 (38.5%) had an intermediate RS,
and 13 (25.0%) had high RS. All patients with high RS tumors also had high-SUV tumors.
Next, RS was dichotomized using a cut-off point of 26, as ongoing clinical trials that have
incorporated RS defined high-risk patients as having an RS26 [13]. Of the 115 patients with
low-SUV tumors, 114 [99.1% (95% confidence interval [CI], 97.4–100.0)] had tumors with a
SUV and recurrence score
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lower RS. Of the 52 patients with high-SUV tumors, 23 [44.2% (95% CI, 30.7–57.7)] had
tumors with higher RS.
Moreover, when we compared the mean RS according to dichotomized SUV, a significant
difference was observed, with 14.8±5.6 in the low SUV group vs. 24.0±12.1 in the high SUV
group (P< 0.001; Fig 3).
To identify biological differences between the two markers, we compared characteristics
among the groups according to SUV and RS agreement or discordance (Table 2). One hun-
dred and sixty-seven patients were accordingly divided into three groups: low SUV-lower RS
(lSUV/lRS; n = 114), discordant SUV-lower RS (discordant; hSUV/lRS; n = 30), and high
SUV-higher RS (hSUV/hRS; n = 23).
First, when compared with the hSUV/hRS group, the lSUV/lRS group tended to have
tumors with a smaller size, lower stage, lower grade, higher PR expression, and lower Ki67
expression, compared with the hSUV/hRS group.
The discordant group had significantly higher grades and larger tumors, compared with the
lSUV/lRS group (P< 0.001 and P = 0.001, respectively). In addition, this group had a signifi-
cantly higher rate of high-Ki67 (20%) tumors than did the lSUV/lRS group (P = 0.006). In
contrast, PR expression did not differ significantly between the two groups. By contrast, when
the discordant group and hSUV/hRS group were compared, the latter had lower rates of
tumors with high PR expression (P< 0.001). The groups did not differ with respect to other
pathologic factors.
Table 1. Concordance between categorized SUV and categorized RS.
Low SUV (N = 115) High SUV (N = 52)
RS Low (N = 97) 73 (66.4) 19 (36.5)
Intermediate (N = 57) 37 (33.6) 20 (38.5)
High (N = 13) 0 (0) 13 (25.0)
d-RS Lower-RS (25) (N = 143) 109 (99.1) 29 (55.8)
Higher-RS (>25) (N = 24) 1 (0.9) 23 (44.2)
Abbreviations: d-RS, dichotomized-recurrence score; SUV, standardized uptake value
https://doi.org/10.1371/journal.pone.0175048.t001
Fig 2. Scatter plots of continuous standardized uptake values (SUV) and continuous recurrence scores (RS). (A) Continuous SUV
and continuous RS (Pearson’s R = 0.555; P < 0.001); (B) Continuous SUV and continuous progesterone receptor expression (reverse
transcriptase-polymerase chain reaction [RT-PCR]) (Pearson’s R = -0.408; P < 0.001); (C) Continuous SUV and continuous estrogen
expression by RT-PCR (Pearson’s R = -0.014; P = 0.856). Footnote: CT, normalized expression cycle threshold levels.
https://doi.org/10.1371/journal.pone.0175048.g002
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Lastly, we compared the mean PR scores among the three groups (Fig 4). This comparison
demonstrated the mean PR scores did not differ between the lSUV/lRS and discordant groups.
Collectively, these results indicate that the SUV positively reflects tumor proliferation, as deter-
mined via Ki67 or histologic analysis, to a greater extent compared to RS (S1 Fig), whereas RS
is largely affected by the degree of PR expression and is more sensitive than SUV in these spe-
cific tumors.
Logistic regression analysis
Variables with p< 0.05 on univariate analysis—including SUV, tumor size, stage, PR expres-
sion, and Ki67—were entered as input variables in multivariate analysis in order to distinguish
higher RS (26). Multivariate analysis revealed that SUV and PR expression remained inde-
pendent variables associated with higher RS (Table 3). Among these, SUV demonstrated the
highest odds ratio (OR = 100.62; 95% CI = 10.01–1003.64) for predicting higher RS on the
multivariate analysis. The area under the receiver operating characteristic curve for continuous
SUV was 0.928 (95% CI, 0.884–0.972, P<0.001) for distinguishing higher RS from lower RS
(S2 Fig).
Adjuvant treatment according to RS or SUV
Of the 115 patients with low SUV tumors, 91.3% (95% CI, 86.2–96.5; n = 105) received endo-
crine treatment, and 8.7% (95% CI, 3.5–13.8; n = 10) received chemo-endocrine treatment (S2
Table). Of the 143 patients with lower RS tumors, 131 [91.6% (95% CI, 87.1–96.2)] received
Fig 3. Distributions and means of recurrence scores (RS) according to categorized standardized
uptake values (SUV). The mean RS were 14.8 in the low SUV group and 24.0 in the high SUV group
(P < 0.001).
https://doi.org/10.1371/journal.pone.0175048.g003
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endocrine treatment alone, and 12 [8.4% (95% CI, 3.8–12.9)] received adjuvant chemotherapy
followed by endocrine therapy.







P b P c P d P e
Histology 0.024 0.032 1.000 0.084
IDC 86 (75.4) 29 (96.7) 22 (95.7)
ILC 15 (13.2) 0 (0) 0 (0)
Others 13 (11.4) 1 (3.3) 1 (4.3)
Tumor size <0.001 0.001 1.000 0.001
2cm 101 (88.6) 18 (60.0) 13 (56.5)
>2cm 13 (11.4) 12 (40.0) 8 (43.5)
Nodal status 0.710 0.841 0.349 0.452
Negative 99 (86.8) 25 (83.3) 22 (95.7)
Micrometastasis 4 (3.5) 1 (3.3) 0 (0)
Positive 11 (9.6) 4 (13.3) 1 (4.3)
Stage
IA 87 (76.3) 17 (56.7) 12 (52.2) 0.001 0.006 0.138 0.029
IB 4 (3.4) 1 (3.3) 0 (0)
IIA 22 (19.3) 8 (26.7) 11 (47.8)
IIB 1 (0.9) 4 (13.3) 0 (0)
Histologic grade <0.001 <0.001 0.246 <0.001
I 36 (31.6) 1 (3.3) 2 (8.7)
II 73 (64.0) 21 (70.0) 11 (47.8)
III 3 (2.6) 8 (26.7) 10 (43.5)
Unknown 2 (1.8) 0 (0) 0 (0)
Estrogen receptor a 0.859 0.614 0.488 0.905
Strong 101 (88.6) 28 (93.3) 20 (87.0)
Moderate 10 (8.8) 2 (6.7) 2 (8.7)
Weak 3 (2.6) 0 (0) 1 (4.3)
Negative 0 (0) 0 (0) 0 (0)
Progesterone
receptor a
0.002 0.426 <0.001 0.002
Strong 59 (51.8) 18 (60.0) 3 (13.0)
Moderate 28 (24.6) 9 (30.0) 6 (26.1)
Weak 12 (10.5) 1 (3.3) 6 (26.1)
Negative 15 (13.2) 2 (6.7) 8 (34.8)
Ki67 <0.001 0.006 0.087 <0.001
<20% 104 (91.2) 22 (73.3) 11 (47.8)
20% 8 (7.0) 8 (26.7) 12 (52.2)
Unknown 2 (1.8) 0 (0) 0 (0)
a Strong, Allred score 7–8; Moderate, Allred score 5–6; Weak, Allred score 2–4.
b Characteristics among the three groups were compared using the χ2 test.
c Characteristics were compared between two groups using the χ2 test (Low SUV-Lower RS vs. Discordant SUV-RS).
d Characteristics were compared between two groups using the χ2 test (Discordant RS vs. High SUV-Higher RS).
e Characteristics were compared between two groups using the χ2 test (Low SUV-Lower RS vs. High SUV-Higher RS).
Abbreviations: SUV, standardized uptake value; RS, recurrence score; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma
https://doi.org/10.1371/journal.pone.0175048.t002
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Among patients with high risk factors, 24 of 51 patients (47.1%, 95% CI, 33.3–60.8) with
high SUV received chemo-endocrine treatment, whereas 22 of 23 women (95.7%, 95% CI
87.3–100.0) with higher RS received chemotherapy. One patient was excluded from the analy-
sis because of a refusal of adjuvant chemotherapy, despite a high RS of 38.
Discussion
In our evaluation of biologic parameters with continuous function, we observed a certain
degree of correlation between the SUV on 18F-FDG-PET-CT and RS in ER-positive, HER2-
negative breast cancer. We showed that tumors with low SUV have a very high probability in
having lower RS. In addition, our multivariate analysis revealed that high SUV (4) is inde-
pendent factor associated with higher RS (26).
It is known that proliferation modules within multigene assays, including RS, are a com-
mon driving force behind the overall prognostic assay performance [14,15]. Also, previous
studies provided evidence that tumors with increased glucoe uptkae have high proflierative
Fig 4. Average PR expression among the three groups, divided by dichotomized SUV and
dichotomized RS groups (low SUV-lower RS, the discordant, and high SUV-higher RS). The mean PR
expression, determined using reverse transcriptase-polymerase chain reaction, of the high SUV-higher RS
was significantly higher than that of the discordant group or the low SUV-lower RS group (P < 0.001 and
P < 0.001, respectively; All P-values by the Student’s t-test). However, the mean PR scores (CT) did not differ
between the low SUV-lower RS and the discordant groups (P = 0.810). Footnote: CT, normalized expression
cycle threshold levels.
https://doi.org/10.1371/journal.pone.0175048.g004
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propensities [9,10]. Therefore, some degree of concordance was expected between the SUV
and RS. In our study, SUV also correlated with the Ki67 index and histologic grade, further
confirming SUV provides a good reflection of tumor proliferation (S1 Fig). These findings
provide biological evidence to support a prognostic value of SUV for luminal cancer, as sug-
gested by our previous work.
Interestingly, we found an inverse correlation between the PR score and SUV. Recently, in
a study of patients with ER-positive/HER2-negative disease, similar to those in our study, Prat
et al. reported that semi-quantitative PR IHC analysis has improved in terms of identifying
women with a good prognosis [16]. Currently, the use of a tumor’s PR status to identify lumi-
nal B/HER2-negative disease is recommended by St. Gallen’s guideline [4]. The absence of PR
has long been regarded as an indicator of an impaired ER signaling pathway. In addition, the
loss of PR is associated with the activation of cross-talk between the ER and growth factor sig-
naling pathway [17]; this cross-talk may upregulate growth factor signaling and potentially
contribute to increased glycolysis in PR-lacking tumors, as growth factor signaling plays a cru-
cial role in the Warburg effect [18]. Further studies to elucidate the relationship between the
loss of PR and increased glycolytic activity in this subset of breast cancer are warranted.
In analyses based on categorized RS and SUV, tumors with a low SUV tended to have a
lower RS. In the low-SUV group, a high concordance rate (99.1%) was observed between a low
SUV and lower RS. However, in patients with high SUV-tumors, a substantial discrepancy
between the two markers was noted.
In further analyses of the discordance between two markers, the high SUV-lower RS group
exhibited distinctive biological characteristics, compared with the concordant groups. The dis-
cordant group had either higher grade or higher Ki67 index when compared with the low
SUV-lower RS group, and can therefore be considered a middle group between the two con-
cordant groups in terms of pathologic factors such as the grade or Ki67 index. In accordance
with these findings, the mean SUV increased stepwise among the three groups (data not
shown).
Table 3. Binary logistic regression analysis for factors associated with higher recurrence score (26).
Variables Univariate (P) Multivariate (P) Odds Ratio 95% CI
SUV <0.001 <0.001 100.62 10.01–1003.64
<4 vs.4
Tumor size 0.010 0.764 2.51 0.01–1026.26
2cm vs. >2cm
Nodal status 0.251
Negative or Micrometastasis vs. Positive
Stage 0.034 0.785 2.29 0.01–885.23
I vs. II
Histologic grade <0.001 0.811 1.20 0.27–5.24
I or II vs. III
Estrogen receptor a 0.548
Higher vs. Lower
Progesterone receptor a <0.001 0.005 7.68 1.88–31.39
Higher vs. Lower
Ki67 <0.001 0.083 3.15 0.86–11.56
<20% vs.20%
a Higher, Allred score 5–8; Lower, Allred score 0–4.
https://doi.org/10.1371/journal.pone.0175048.t003
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By contrast, the average RS did not exhibit a stepwise pattern among the three groups. The
mean RS in the discordant group was similar to that in the low SUV-lower RS group, but sig-
nificantly lower than that in the high SUV-higher RS group (data not shown). Correspond-
ingly, we observed similar PR scores between the low SUV-lower RS and the discordant group,
whereas this score was significantly lower in the high SUV-higher RS group, compared with
the discordant group (Fig 4). These results suggest that the RS might be very sensitive to PR
expression, whereas the SUV might rely more strongly on proliferation indices such as Ki67 or
the histologic grade. Indeed, in the tumors from our study, the absolute Pearson’s R value was
higher for the correlation of the RS and PR score than for that of the RS and SUV (-0.735 vs.
0.555).
The strong interaction between PR expression and RS observed in our study can be
explained by the fact that all of our patients had ER-positive, HER2-negative tumors. Because
the RS was originally developed for ER-positive cancer cohorts, regardless of HER2 expression,
and is strongly affected by the HER2 score, the influence of PR expression becomes more pro-
nounced in our ER-positive, HER2-negative patients.
Taken together, our findings show that SUV, when used as a biologic parameter with con-
tinuous function, is associated with the RS in ER-positive, HER2-negative breast cancer.
Despite the good accordance observed between SUV and RS, a certain group of patients exhib-
ited discordance between these two markers at an individual level. These observations are pre-
dominantly attributed to biologic differences in these markers; specifically, RS is more
sensitized to PR expression, whereas SUV is more strongly affected by histologic grade or Ki67
expression in ER-positive/HER2-negative cancers.
Furthermore, we investigated the actual use of adjuvant treatment according to the dichoto-
mized SUV in a whole study population. We found that 105 of 115 (91.3%) in the patients with
low SUV tumors had received endocrine treatment alone. Among patients with high SUV
tumors, however, 47.1% received chemo-endocrine treatment, suggesting that according to
current evidence, high SUV is not a determinant with regard to the addition of chemotherapy
for patients with ER-positive/HER2-negative disease. Nevertheless, in addition to the high
level of agreement between a low SUV and lower RS, the higher rate of endocrine treatment-
only patients in the low-SUV group, which is comparable with lower RS (25), provides evi-
dence of the potential clinical usefulness of SUV, at least with regard to identifying patients
with a low recurrence risk.
One major limitation of our study is the absence of survival analyses among the divided
groups by two markers because of the short follow-up duration. The clinical outcomes of our
study population might help to refine prognostic discrimination according to these markers.
Another limitation is selection bias; the RS is financially expensive, and therefore, RS were
only obtained for a fraction of ER-positive/HER2-negative patients during the study period. In
addition, we were unable to conduct a comparative analysis between the SUV and each of the
16 genes comprising the RS because we did not receive information regarding the expression
levels of these genes. We note that information about the expression levels of other genes that
comprise the RS could enhance our knowledge of the relationship between RS and SUV and
our understanding of the biological characteristics underlying accordance or discordance
between these factors.
Despite these limitations, we have provided novel evidence to support that the biologic
parameter of glucose uptake magnitude correlates with RS; in turn, these findings support the
prognostic value of the SUV for ER-positive, HER2-negative breast cancer. Further studies are
warranted to determine the potential of SUV for the identification of risk groups among the
patients with a lower RS.
SUV and recurrence score
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Conclusions
In conclusion, SUV as biologic parameters with continuous function was found to associate
with RS in ER-positive, HER2-negative breast cancer. Further studies may reveal the biology
underlying the discordance between the markers.
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